A decision-focused study plan that states the development question, material constraints, techniques selected, and the evidence level the work is intended to support.
Evaluate whether solid-state claims are experimentally supported, reproducible, and defensible.
Evaluate whether solid-state claims are experimentally supported, reproducible, and defensible.
When this page is the right starting point
Evaluate whether solid-state claims are experimentally supported, reproducible, and defensible.
- Counsel or technical teams need scientific evidence tied to novelty, reproducibility, enablement, claim support, infringement, validity, freedom to operate, prior art, or expert-position development.
- Solid forms, analytical methods, formulations, hydrates, solvates, salts, cocrystals, amorphous forms, impurities, or material properties are central to a patent position.
- A legal team needs technical data that can survive scrutiny, be reproduced where necessary, and be explained clearly without overstating what the experiments prove.
How Triclinic Approaches Patent Strength Assessment for Solid-State Pharmaceutical Forms
Triclinic approaches patent-strength assessment by translating legal or business questions into testable solid-state questions. The work is scientific support for counsel, not legal advice.
The workflow evaluates whether claimed forms or properties are analytically distinguishable, reproducible, enabled by the disclosure, and supported by credible experimental data. That may require reviewing prior art, reproducing examples, comparing polymorphs, salts, cocrystals, hydrates, solvates, amorphous forms, or formulations, and assessing limitations of the analytical methods used in the claim or example.
Strong solid-state patent support usually depends on more than a single XRPD pattern or thermal event. Orthogonal evidence may be needed to address form identity, stoichiometry, hydration, solvation, purity, crystallinity, structure, reproducibility, and whether differences are material or experimental artifacts.
The output should make the evidentiary record clearer: what the data support, what they do not support, what can be reproduced, what remains ambiguous, and what additional experiments would strengthen or weaken the position.
Questions the technical record should answer
- Which claim, prior-art question, lifecycle decision, or legal position must the scientific evidence address?
- Are the claimed solid forms or properties analytically distinct, reproducible, enabled by the disclosure, and supported by appropriate controls?
- Which comparative and orthogonal data are needed to distinguish confirmed findings from assumptions, artifacts, or unresolved technical risk?
Techniques commonly considered
- XRPD
- DSC
- TGA
- Raman
- FTIR
- NMR
- chromatography
- microscopy
- SCXRD
- MicroED
- DVS
- Karl Fischer where relevant
Typical deliverables
Outputs should support a decision, not just report instrument output.
Build the factual record behind solid-form claims
Screening depth can strengthen a patent position by creating the factual record for novelty, utility, non-obviousness, enablement, and claim scope. Strong solid-form support depends on reproducible preparation, analytical distinctness, comparative property data, unexpected advantage, and a clear explanation of why the result was not routine.
Scientific documentation should preserve failed routine paths, comparative results, scale-up evidence, material history, seed/source history, and the technical problem-solution narrative. Development scientists are not patent counsel, but they can supply the evidence that makes a form position easier to evaluate and defend.
| Decision signal | What to test | Actionable output |
|---|---|---|
| What was the challenge? | Prior-art behavior, baseline instability, solubility limit, or process failure. | Document the starting problem and material history. |
| What was unexpected? | Comparative dissolution, hygroscopicity, stability, bioavailability, purification, or manufacturability advantage. | Tie the advantage to a reproducible form and data set. |
| How was it solved? | Screen conditions, seed/source history, counterion/coformer rationale, and scale-up demonstration. | Keep successful and failed experiments in the record. |
| Was it routine? | Evidence that ordinary conditions failed or property gains were not predictable. | Document negative results and non-obvious pathways. |
Examples and Publications.
These examples and publications are included to make the page more useful and verifiable. Each example lists the author, publication date, and a descriptive abstract rather than relying on vague claims.
Other services available
Common Questions
When is Patent Strength Assessment for Solid-State Pharmaceutical Forms the right service?
Use this service when the project needs evidence about solid-form identity, behavior, control, and risk at a level appropriate for the next development, formulation, CMC, manufacturing, regulatory, or IP decision.
How much material is needed?
Material requirements depend on the question, the number of conditions, the technique mix, detection limits, and whether the work is screening-level, confirmatory, quantitative, cGMP-capable, or intended for legal or regulatory support. Triclinic can often scope staged work around limited material, but exact amounts should be confirmed during project intake.
Which techniques may be used?
Technique selection depends on the scientific question and sample constraints. XRPD, DSC, TGA, Raman, FTIR, microscopy, DVS, Karl Fischer, chromatography, NMR, SCXRD, MicroED, dissolution, stability, and particle methods may be considered where relevant. Orthogonal evidence is often needed to separate form, chemistry, water or solvent, morphology, processing history, and analytical artifacts.
Can this support formulation, CMC, manufacturing, regulatory, or IP decisions?
Yes, when the work is scoped to the decision and evidence standard required. The goal is defensible scientific data and interpretation for development, formulation, CMC, manufacturing, regulatory, and IP contexts, not a guarantee of a regulatory, legal, or commercial outcome.
Can Triclinic reproduce patent examples or prior art?
Yes, when the cited procedure, materials, assumptions, and reasonable experimental variables can be defined. The work should document ambiguities, deviations, observations, analytical results, reproducibility, and the limits of the scientific conclusions.
Talk to a Triclinic Labs scientist about Patent Strength Assessment
Send the patent or prior-art question, relevant claims and examples, material history, existing analytical data, comparison materials, and decision timeline. Triclinic will route the request to the right solid-state and IP-support scientist.
